113225-19-7

Basic information

• Product Name: 3-PIPERIDINOL, 1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-, (3S,4R)-
• Synonyms: 3-PIPERIDINOL, 1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-, (3S,4R)-;(3S,4R)-1-Methyl-4-(2,4,6-triMethoxyphenyl)-3-piperidinol
• CAS NO: 113225-19-7
• Molecular Formula: C₁₅H₂₃NO₄
• Molecular Weight: 281.35
• Mol File: 113225-19-7.mol

Chemical Properties

• Melting Point: 111-112 °C
• Boiling Point: 406.536°C at 760 mmHg
• Flash Point: 199.666°C
• Appearance: /
• Density: 1.122g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.53
• PKA: 14.55±0.40(Predicted)
• CAS DataBase Reference: 3-PIPERIDINOL, 1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-, (3S,4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PIPERIDINOL, 1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-, (3S,4R)-(113225-19-7)
• EPA Substance Registry System: 3-PIPERIDINOL, 1-METHYL-4-(2,4,6-TRIMETHOXYPHENYL)-, (3S,4R)-(113225-19-7)

Safety Data

• Hazardous Substances Data: 113225-19-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C15H23NO4/c1-16-6-5-11(12(17)9-16)15-13(19-3)7-10(18-2)8-14(15)20-4/h7-8,11-12,17H,5-6,9H2,1-4H3/t11-,12+/m0/s1

Upstream product

• 113225-07-3 1-methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydropyridine 
• 1445-73-4 1-Methyl-4-piperidone 
• 621-23-8 1,2,3-trimethoxybenzene 
• 113225-10-8 (+)-1-Methyl-4-(2,4,6-trimethoxyphenyl)-piperidin-3-one 
• 113225-08-4 (±)-trans-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidin-3-ol 
• 205506-14-5 (R)-1-methyl-4-(2,4,6-trimethoxyphenyl)-3-piperidinone 

Downstream Products

• 117955-09-6 (±)-trans-[1-methyl-3-(2,4,6-trimethoxyphenyl)pyrrolidin-2-yl]methanol 
• 113225-10-8 (+)-1-Methyl-4-(2,4,6-trimethoxyphenyl)-piperidin-3-one 
• 113225-08-4 cis-1-methyl-4-(2,4,6-trimethoxyphenyl)-3-piperidinol 
• 920112-97-6 (-)-trans-[1-methyl-3-(2,4,6-trimethoxyphenyl)pyrrolidin-2-yl]methanol 
• 1000023-98-2 [1-methyl-3-(2,4,6-trimethoxyphenyl)pyrrolidin-2-yl]methanol 
• 920112-99-8 ((-)-trans-acetic acid-3-(3-acetyl-2-hydroxy-4,6-dimethoxyphenyl)-1-methylpyrrolidin-2-yl)methyl ester 
• 1622998-49-5 (-)-trans-2-(2-(acetoxymethyl)-1-methylpyrrolidin-3-yl)-6-acetyl-3,5-dimethoxyphenyl-2-chlorobenzoate 
• 920113-01-5 (+)-trans-2-(2-chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one 
• 920113-02-6 (+)-trans-2-(2-chloro-phenyl)-5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-chromen-4-one 
• 920113-03-7 (+)-2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-4H-chromen-4-one hydrochloride 
• 1254504-57-8 C₁₅H₂₃NO₄*C₁₈H₁₄O₈ 
• 1623001-48-8 C₁₅H₂₃NO₄*C₁₈H₁₄O₈ 

Relevant articles and documents

PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER

The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of f

AN IMPROVED PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES

The present invention relates to a process for the preparation of a key intermediate (as described herein) used in the synthesis of (+)-trans enantiomer of pyrrolidine substituted flavones, represented by the compounds of formula (1) or pharmaceutically a

A PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES

The present invention relates to a process for the preparation of a key intermediate (as described herein) used in the synthesis of (+)-trans enantiomer of pyrrolidine substituted flavones, represented by the compounds of formula (1) or pharmaceutically a

CYTOKINE INHIBITORS

The present invention provides compounds represented by general formula (I): wherein, R1; R2, R3, L and T are as defined in the specification, in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, and prodrugs thereof. The invention also relates to processes for the manufacture of compounds of formula (I) and pharmaceutical compositions containing them. The compounds and the pharmaceutical compositions of the present invention are useful in the treatment of a condition or disorder mediated by one or more cytokines selected from Tumor Necrosis Factor-alpha (TNF-oc) and interleukins such as IL-1, IL-6, and IL-8. The present invention further provides a method of treatment of inflammatory disorders by administering a therapeutically effective amount of the said compound of formula (I) or its pharmaceutical composition, to a mammal in need thereof.

NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

The present invention relates to an enantiomerically pure (+)-trans-enantiomer of a compound represented by the following formula (I): wherein R1, R2, R3, R4 and R9 are as defined in the specification; enantiomerically pure intermediates thereof, to processes for the preparation of the enantiomerically pure compound and its intermediates, and to a pharmaceutical composition comprising the enantiomerically pure compound. The compound of formula (I) is useful for the treatment of diseases or disorders mediated by the inhibition of cyclin dependant kinase, such as cancer.

ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION

The present invention relates to an enantiomerically pure (+)-trans-enantiomer of a compound represented by the following formula (I): wherein R1, R2, R3, R4 and R9 are as defined in the specification; enantiomerically pure intermediates thereof, to processes for the preparation of the enantiomerically pure compound and its intermediates, and to a pharmaceutical composition comprising the enantiomerically pure compound. The compound of formula (I) is useful for the treatment of diseases or disorders mediated by the inhibition of cyclin dependant kinase, such as cancer.

Preparation of 4-phenyl-1,2,3,6-tetrahydropyridines

A process for the preparation of a compound of the formula wherein R1 is selected from the group consisting of hydrogen and alkyl of 1 to 8 carbon atoms, R2 and R4 are alkyl of 1 to 4 carbon atoms and R3 is alkyl of 1 to 8 carbon atoms comprising reacting a compound of the formula wherein R1, R2, R3 and R4 are defined as above or an amine salt thereof with an electrophilic halogenating agent to obtain a compound of the formula wherein Hal1 is halogen, reacting the latter with a halohydroxylating agent to obtain a compound of the formula wherein Hal2 is halogen, reacting the latter with a base to obtain a compound of the formula reacting the latter with a diastereoselective reducing agent to obtain a compound of the formula reacting the latter with a reducing agent to obtain a cis racemic compound of formula I and optionally resolving the latter with a resolution agent to obtain the desired optical form and novel intermediates.

Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: Synthesis and biological effects

Flavopiridol analogues, thio- and oxoflavopiridols which contain a sulfur (16) or oxygen (18) atom tinker between a chromone ring and the hydrophobic side chain, are selective cyclin-dependent kinase 1 (CDK1) inhibitors with an IC50 of 110 and

4H-1-benzopyran-4-one compounds which have anti-inflamatory or immunodulating action

The present invention relates to novel 4H-1-benzopyran-4-one derivatives, to processes for the preparation thereof and to their use as anti-inflammatory, analgesic, immuno-suppressive and anti-allergic agents. In particular, the present invention relates to novel compounds of the formula I, STR1 in which R1 is hydrogen, alkyl having 1 to 6 carbon atoms, arly-C1 -C4 -alkyl, substituted C1 -C6 -alkyl, C3 -C6 -cycloalkyl, C3 -C6 -cycloalkyl-C1 -C4 -alkyl, C2 -C6 -alkenyl, C3 -C6 -alkynyl, aryl or carboxyl or an aldehyde or COO--C1 -C4 -alkyl group, R2 is hydrogen, alkyl having 1 to 6 carbon atoms, nitro, amino, di-C1 -C4 -alkylamino or a halogen, R3 is C1 -C4 -alkyl, substituted C1 -C4 -alkyl, hydroxyl, C1 -C4 -alkoxy, aryl-C1 -C4 -alkyl, nitro, amino, a C1 -C4 -alkylamino or di-C1 -C4 -alkylamino group or halogen, R4 is hydrogen, hydroxyl, C1 -C4 -alkyoxy, C1 -C4 -alkyoxycarbonyl, aryloxy, amino or a C1 -C4 -alkylamino or di-C1 -C4 -alkylamino group, R5 is hydrogen, C1 -C6 -alkyl, substituted C1 -C6 -alkyl, aryl-C1 -C4 -alkyl, C3 -C6 -cycloalkyl, C3 -C6 -cycloalkyl-C1 -C4 -alkyl, C1 -C4 -alkanoyl or aroyl, the aryl group being phenyl which is unsubstituted, monosubstituted or polysubstituted, m is an integer between 0 and 3 and n is an integer between 0 and 2, and to pharmacologically acceptable acid addition salts thereof.